Which has better valuation and earnings, LNTH or ANAB?

Lantheus has higher revenue and earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.55B 4.63 $233.56M $4.15 26.48 AnaptysBio $232.39M 8.08 -$13.23M -$1.08 N/A

Is LNTH or ANAB more profitable?

Lantheus has a net margin of 18.05% compared to AnaptysBio's net margin of -11.53%. Lantheus' return on equity of 29.32% beat AnaptysBio's return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% AnaptysBio -11.53% N/A -7.75%

AnaptysBio (ANAB) Competitors

$63.42 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$63.48 +0.06 (+0.09%)

As of 07/2/2026 06:27 PM Eastern

Compare

ANAB vs. LNTH, PTCT, MIRM, CNTA, and COGT

Should you buy AnaptysBio stock or one of its competitors? MarketBeat compares AnaptysBio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AnaptysBio include Lantheus (LNTH), PTC Therapeutics (PTCT), Mirum Pharmaceuticals (MIRM), Centessa Pharmaceuticals (CNTA), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry.

How does AnaptysBio compare to Lantheus?

Lantheus (NASDAQ:LNTH) and AnaptysBio (NASDAQ:ANAB) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Lantheus had 4 more articles in the media than AnaptysBio. MarketBeat recorded 4 mentions for Lantheus and 0 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 0.00 beat Lantheus' score of -0.30 indicating that AnaptysBio is being referred to more favorably in the news media.

Company	Overall Sentiment
Lantheus	Neutral
AnaptysBio	Neutral

Lantheus presently has a consensus price target of $101.86, indicating a potential downside of 7.31%. AnaptysBio has a consensus price target of $81.82, indicating a potential upside of 29.01%. Given AnaptysBio's higher possible upside, analysts clearly believe AnaptysBio is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Lantheus has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

99.1% of Lantheus shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Comparatively, 31.5% of AnaptysBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Lantheus has higher revenue and earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.55B	4.63	$233.56M	$4.15	26.48
AnaptysBio	$232.39M	8.08	-$13.23M	-$1.08	N/A

Lantheus has a net margin of 18.05% compared to AnaptysBio's net margin of -11.53%. Lantheus' return on equity of 29.32% beat AnaptysBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
AnaptysBio	-11.53%	N/A	-7.75%

Summary

Lantheus beats AnaptysBio on 10 of the 16 factors compared between the two stocks.

How does AnaptysBio compare to PTC Therapeutics?

AnaptysBio (NASDAQ:ANAB) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

AnaptysBio has a net margin of -11.53% compared to PTC Therapeutics' net margin of -22.58%. AnaptysBio's return on equity of 0.00% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	N/A	-7.75%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

AnaptysBio presently has a consensus price target of $81.82, indicating a potential upside of 29.01%. PTC Therapeutics has a consensus price target of $91.36, indicating a potential upside of 9.66%. Given AnaptysBio's higher possible upside, equities analysts plainly believe AnaptysBio is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.71

PTC Therapeutics has higher revenue and earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$232.39M	8.08	-$13.23M	-$1.08	N/A
PTC Therapeutics	$1.73B	3.99	$682.64M	-$2.33	N/A

In the previous week, PTC Therapeutics had 7 more articles in the media than AnaptysBio. MarketBeat recorded 7 mentions for PTC Therapeutics and 0 mentions for AnaptysBio. PTC Therapeutics' average media sentiment score of 0.99 beat AnaptysBio's score of 0.00 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
AnaptysBio	Neutral
PTC Therapeutics	Positive

AnaptysBio has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

Summary

PTC Therapeutics beats AnaptysBio on 8 of the 14 factors compared between the two stocks.

How does AnaptysBio compare to Mirum Pharmaceuticals?

AnaptysBio (NASDAQ:ANAB) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

AnaptysBio has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market.

In the previous week, Mirum Pharmaceuticals had 12 more articles in the media than AnaptysBio. MarketBeat recorded 12 mentions for Mirum Pharmaceuticals and 0 mentions for AnaptysBio. Mirum Pharmaceuticals' average media sentiment score of 0.75 beat AnaptysBio's score of 0.00 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
AnaptysBio	Neutral
Mirum Pharmaceuticals	Positive

AnaptysBio currently has a consensus target price of $81.82, indicating a potential upside of 29.01%. Mirum Pharmaceuticals has a consensus target price of $143.00, indicating a potential upside of 13.86%. Given AnaptysBio's higher probable upside, equities analysts plainly believe AnaptysBio is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

AnaptysBio has higher earnings, but lower revenue than Mirum Pharmaceuticals. AnaptysBio is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$232.39M	8.08	-$13.23M	-$1.08	N/A
Mirum Pharmaceuticals	$521.31M	14.69	-$23.36M	-$13.61	N/A

AnaptysBio has a net margin of -11.53% compared to Mirum Pharmaceuticals' net margin of -140.24%. AnaptysBio's return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	N/A	-7.75%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Summary

Mirum Pharmaceuticals beats AnaptysBio on 9 of the 15 factors compared between the two stocks.

How does AnaptysBio compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and AnaptysBio (NASDAQ:ANAB) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Centessa Pharmaceuticals has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
AnaptysBio	-11.53%	N/A	-7.75%

Centessa Pharmaceuticals currently has a consensus price target of $41.33, indicating a potential upside of 2.06%. AnaptysBio has a consensus price target of $81.82, indicating a potential upside of 29.01%. Given AnaptysBio's stronger consensus rating and higher possible upside, analysts plainly believe AnaptysBio is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

In the previous week, Centessa Pharmaceuticals had 1 more articles in the media than AnaptysBio. MarketBeat recorded 1 mentions for Centessa Pharmaceuticals and 0 mentions for AnaptysBio. Centessa Pharmaceuticals' average media sentiment score of 0.00 equaled AnaptysBio'saverage media sentiment score.

Company	Overall Sentiment
Centessa Pharmaceuticals	Neutral
AnaptysBio	Neutral

AnaptysBio has higher revenue and earnings than Centessa Pharmaceuticals. AnaptysBio is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A
AnaptysBio	$232.39M	8.08	-$13.23M	-$1.08	N/A

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by company insiders. Comparatively, 31.5% of AnaptysBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Centessa Pharmaceuticals has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

Summary

AnaptysBio beats Centessa Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does AnaptysBio compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and AnaptysBio (NASDAQ:ANAB) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

Cogent Biosciences has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

In the previous week, Cogent Biosciences had 2 more articles in the media than AnaptysBio. MarketBeat recorded 2 mentions for Cogent Biosciences and 0 mentions for AnaptysBio. Cogent Biosciences' average media sentiment score of 0.25 beat AnaptysBio's score of 0.00 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cogent Biosciences	Neutral
AnaptysBio	Neutral

Cogent Biosciences presently has a consensus target price of $43.73, indicating a potential upside of 13.02%. AnaptysBio has a consensus target price of $81.82, indicating a potential upside of 29.01%. Given AnaptysBio's higher possible upside, analysts plainly believe AnaptysBio is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

AnaptysBio has higher revenue and earnings than Cogent Biosciences. AnaptysBio is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
AnaptysBio	$232.39M	8.08	-$13.23M	-$1.08	N/A

Cogent Biosciences has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
AnaptysBio	-11.53%	N/A	-7.75%

Summary

AnaptysBio beats Cogent Biosciences on 8 of the 14 factors compared between the two stocks.

Get AnaptysBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANAB vs. The Competition

Export

Metric	AnaptysBio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.88B	$3.78B	$7.17B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-58.72	21.61	28.02	24.70
Price / Sales	8.08	342.06	540.72	98.05
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	47.33	8.66	10.96	6.46
Net Income	-$13.23M	$23.81M	$3.57B	$337.01M
7 Day Performance	0.43%	3.39%	2.12%	1.69%
1 Month Performance	25.91%	10.81%	5.25%	3.81%
1 Year Performance	163.76%	62.61%	33.29%	23.90%

AnaptysBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANAB AnaptysBio	2.679 of 5 stars	$63.42 flat	$81.82 +29.0%	+163.8%	$1.88B	$232.39M	N/A	100	Gap Up High Trading Volume
LNTH Lantheus	2.618 of 5 stars	$104.85 -1.1%	$101.86 -2.9%	+38.7%	$6.90B	$1.54B	25.27	1,193
PTCT PTC Therapeutics	3.0807 of 5 stars	$84.41 +2.8%	$91.36 +8.2%	+70.8%	$6.81B	$1.73B	N/A	1,410	Insider Trade Gap Down
MIRM Mirum Pharmaceuticals	2.3316 of 5 stars	$114.77 +3.3%	$139.80 +21.8%	+151.5%	$6.77B	$521.31M	N/A	140	News Coverage Analyst Forecast Insider Trade Gap Down
CNTA Centessa Pharmaceuticals	1.1286 of 5 stars	$40.71 +0.5%	$41.33 +1.5%	N/A	$6.27B	$15M	N/A	200	Short Interest Decrease High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANAB) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AnaptysBio (ANAB) Competitors

ANAB vs. LNTH, PTCT, MIRM, CNTA, and COGT

How does AnaptysBio compare to Lantheus?

Summary

How does AnaptysBio compare to PTC Therapeutics?

Summary

How does AnaptysBio compare to Mirum Pharmaceuticals?

Summary

How does AnaptysBio compare to Centessa Pharmaceuticals?

Summary

How does AnaptysBio compare to Cogent Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB vs. The Competition

AnaptysBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AnaptysBio (ANAB) Competitors

ANAB vs. LNTH, PTCT, MIRM, CNTA, and COGT

How does AnaptysBio compare to Lantheus?

Does the media refer more to LNTH or ANAB?

Do analysts prefer LNTH or ANAB?

Which has more volatility and risk, LNTH or ANAB?

Do insiders & institutionals believe in LNTH or ANAB?

Which has better valuation and earnings, LNTH or ANAB?

Is LNTH or ANAB more profitable?

Summary

How does AnaptysBio compare to PTC Therapeutics?

Is ANAB or PTCT more profitable?

Do analysts recommend ANAB or PTCT?

Which has better earnings and valuation, ANAB or PTCT?

Does the media prefer ANAB or PTCT?

Which has more risk and volatility, ANAB or PTCT?

Summary

How does AnaptysBio compare to Mirum Pharmaceuticals?

Which has more volatility & risk, ANAB or MIRM?

Does the media favor ANAB or MIRM?

Do analysts rate ANAB or MIRM?

Which has better valuation & earnings, ANAB or MIRM?

Is ANAB or MIRM more profitable?

Summary

How does AnaptysBio compare to Centessa Pharmaceuticals?

Is CNTA or ANAB more profitable?

Do analysts rate CNTA or ANAB?

Does the media refer more to CNTA or ANAB?

Which has stronger valuation and earnings, CNTA or ANAB?

Do institutionals and insiders believe in CNTA or ANAB?

Which has more volatility and risk, CNTA or ANAB?

Summary

How does AnaptysBio compare to Cogent Biosciences?

Which has more risk and volatility, COGT or ANAB?

Does the media favor COGT or ANAB?

Do analysts recommend COGT or ANAB?

Which has stronger valuation & earnings, COGT or ANAB?

Is COGT or ANAB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB vs. The Competition

AnaptysBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools